Scarica l'app Stockscreener
13.74
1.51%
-0.206
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché AVTX Giù?
Forum
Previsione
Frazionamento azionario
Avalo Therapeutics Inc Borsa (AVTX) Ultime notizie
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Analysis Recap: Is Avalo Therapeutics Inc in a bullish channel2026 Setups & Momentum Based Trading Ideas - baoquankhu1.vn
Avalo Therapeutics (NASDAQ:AVTX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
H.C. Wainwright raises Avalo Therapeutics price target to $40 on trial confidence - Investing.com
AVTX: HC Wainwright Raises Price Target, Maintains Buy Rating | - GuruFocus
H.C. Wainwright Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Raises Target Price to $40 - Moomoo
Avalo Therapeutics 2025 Financial Review - AlphaStreet
Is Avalo Therapeutics Inc a potential multi bagger2026 Investor Takeaways & AI Forecast Swing Trade Picks - baoquankhu1.vn
AVTX: BTIG Reiterates Buy Rating with $40 Price Target | AVTX St - GuruFocus
Avalo Therapeutics (NASDAQ:AVTX) Earns Buy Rating from BTIG Research - MarketBeat
Mizuho Securities Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Maintains Target Price $39 - Moomoo
AVTX: BTIG Reiterates Buy Rating with $40 Price Target | AVTX Stock News - GuruFocus
BTIG Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Avalo Therapeutics stock maintains Buy rating at BTIG ahead of trial - Investing.com
Key facts: Avalo Therapeutics posts $78.3M 2025 loss; Q4 EPS -$1.13 - TradingView
Guggenheim reiterates Buy rating on Avalo Therapeutics stock By Investing.com - Investing.com Canada
Guggenheim reiterates Buy rating on Avalo Therapeutics stock - Investing.com
Avalo Therapeutics Reports 2025 Financial Results and Prepares for Key Phase 2 LOTUS Trial Data of AVTX-009 in Hidradenitis Suppurativa - Minichart
Avalo Therapeutics 2025 Annual Report: Clinical Pipeline, Regulatory Risks, and Competitive Landscape - Minichart
Avalo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Avalo Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Avalo Therapeutics (NASDAQ:AVTX) Releases Quarterly Earnings Results, Beats Expectations By $1.17 EPS - MarketBeat
Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates - The Manila Times
AVTX: 2025 saw higher R&D spending and net loss, with cash runway projected into 2028 - TradingView
Avalo 10-K: $0.0M Revenue, $78.3M Net Loss — Outlook Through 2028 - TradingView
Avalo Therapeutics (NASDAQ: AVTX) outlines HS trial plans and cash runway - Stock Titan
Avalo Therapeutics (Nasdaq: AVTX) details 2025 loss and LOTUS trial plans - Stock Titan
Avalo nears Q2 results in 250-patient skin disease drug trial - Stock Titan
Earnings Scheduled For March 23, 2026 - Sahm
If You Invested $1,000 in Avalo Therapeutics Inc (AVTX) - Stock Titan
Aug Sectors: Is Avalo Therapeutics Inc a potential multi baggerEarnings Recap Report & Real-Time Market Trend Scan - baoquankhu1.vn
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
AVTX Q4'25 Earnings: revenue estimate is 0 USD - TradingView
Cantor Fitzgerald L. P. Makes New $1.08 Million Investment in Avalo Therapeutics, Inc. $AVTX - MarketBeat
Top Executive Makes Major Move With Avalo Therapeutics Stock - TipRanks
Avalo Therapeutics chief medical officer sells $411k in stock By Investing.com - Investing.com South Africa
Avalo Therapeutics (NASDAQ:AVTX) Insider Sells $411,695.80 in Stock - MarketBeat
Avalo Therapeutics chief medical officer sells $411k in stock - Investing.com
Avalo Therapeutics (AVTX) CMO exercises options, sells 25,492 common shares - Stock Titan
Panic Selling: Is Avalo Therapeutics Inc undervalued by DCF analysisOptions Play & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Avalo Therapeutics, Inc. $AVTX Shares Acquired by Boothbay Fund Management LLC - MarketBeat
[144] Avalo Therapeutics, Inc. SEC Filing - Stock Titan
Cantor Fitzgerald L. P. Acquires New Position in Avalo Therapeutics, Inc. $AVTX - MarketBeat
Boxer Capital Management LLC Invests $1.59 Million in Avalo Therapeutics, Inc. $AVTX - MarketBeat
Ally Bridge Group NY LLC Purchases New Position in Avalo Therapeutics, Inc. $AVTX - MarketBeat
Avalo Therapeutics CEO Teases Q2 Top-Line Data for AVTX-009 Phase 2b HS LOTUS Trial at Conference - MarketBeat
Avalo Therapeutics (AVTX) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Can Avalo Therapeutics Inc. stock hit analyst price targets2025 Earnings Surprises & Safe Swing Trade Setups - Naître et grandir
Avalo Therapeutics Highlights AVTX-009 Plan, Near-Term Phase II HS Data at Healthcare Conference - Defense World
FMR LLC holds 2.13M shares of Avalo Therapeutics (NASDAQ: AVTX) — 11.5% - Stock Titan
AVTX SEC FilingsAvalo Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Avalo Therapeutics (AVTX) awards 80,000 stock options to Chief Legal Officer - Stock Titan
Avalo Therapeutics (AVTX) CSO awarded 95,000 stock options - Stock Titan
[Form 4] Avalo Therapeutics, Inc. Insider Trading Activity - Stock Titan
Avalo Therapeutics (NASDAQ: AVTX) CBO awarded 95,000 stock options - Stock Titan
Avalo Therapeutics (AVTX) CFO awarded 105,000 stock options as equity compensation - Stock Titan
Avalo Therapeutics (AVTX) CEO awarded 286,000-share stock option grant - Stock Titan
Millennium Management LLC Acquires Additional Shares in Avalo Th - GuruFocus
RWA Wealth Partners LLC Cuts Position in Avalo Therapeutics, Inc. $AVTX - MarketBeat
AVTX Should I Buy - Intellectia AI
Avalo Therapeutics Highlights AVTX-009 HS Phase II Catalyst, Cash Runway at Oppenheimer Conference - Yahoo Finance
AVTX: AVTX-009 targets central HS inflammation, with pivotal phase II data expected next quarter - TradingView
TD Cowen reiterates Avalo Therapeutics stock rating citing phase II opportunity - Investing.com South Africa
0.99%
3.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):